Brief: Histogen Announces Week 26 HST-001 Study Results For The Treatment Of Androgenic Alopecia In Men

Histogen

16/02/2021 13:54

Feb 16 (Reuters) - Histogen Inc  HSTO.O :
    * HISTOGEN ANNOUNCES WEEK 26 HST-001 STUDY RESULTS FOR THE
TREATMENT OF ANDROGENIC ALOPECIA IN MEN
    * HISTOGEN INC - HST-001 FOUND TO BE SAFE AND WELL TOLERATED
WITH
NO SERIOUS ADVERSE EVENTS
    * HISTOGEN - AT WEEK 26 TIMEPOINT, PATIENTS TREATED WITH
HST-001
SHOWED STATISTICALLY SIGNIFICANT CHANGE FROM BASELINE IN TOTAL
HAIRS IN TARGET AREA
    * HISTOGEN INC - SIMILAR TO WEEK 18 PRIMARY ENDPOINT
RESULTS,
HST-001 DID NOT ACHIEVE STATISTICAL SIGNIFICANCE AT WEEK 26 WHEN
COMPARED TO PLACEBO
    * HISTOGEN INC - HAVE BEGUN PLANNING FOR A MORE SUBSTANTIVE
CLINICAL TRIAL IN MEN WITH ANDROGENIC ALOPECIA
    * HISTOGEN INC -  ANTICIPATE A MORE SUBSTANTIVE CLINICAL
TRIAL IN
MEN WITH ANDROGENIC ALOPECIA WILL COMMENCE IN SECOND HALF OF
2021

Source text for Eikon:  ID:nGNXbN8w7d 
Further company coverage:  HSTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))